Company Overview of Weill Cornell Medical College, New York
Weill Cornell Medical College, New York is an educational institution.
525 East 68th Street
New York, NY 10065
Key Executives for Weill Cornell Medical College, New York
Weill Cornell Medical College, New York does not have any Key Executives recorded.
Weill Cornell Medical College, New York Key Developments
Weill Cornell Medical College and Cellectis Announces Research Alliance Advancing Drug Discovery and the Translation of Novel Immunotherapies in Leukemia
Jun 2 15
Weill Cornell Medical College and Cellectis have entered into a strategic translational research alliance to accelerate the development of a targeted immunotherapy for patients with acute myelogenous leukemia (AML), a deadly blood cancer. The alliance will foster the development of Cellectis lead product candidate in AML, called UCART123. The collaboration combines Weill Cornell's broad expertise and resources in translational stem cell science and developmental therapeutics with Cellectis work in development and manufacturing of gene edited CAR-T cell product candidates, a special kind of immune cell that includes an antibody-derived receptor. The research will be led by co-principal investigators Dr. Gail J. Roboz, director of the leukemia program and an associate professor of medicine at Weill Cornell, and Dr. Monica Guzman, an assistant professor of pharmacology in medicine at Weill Cornell. Dr. Roboz is an internationally recognized leader in the field of acute leukemia and will design and implement clinical testing of UCART123 in patients with AML. Dr. Guzman is a renowned leukemia stem cell biologist who specializes in preclinical and early-stage testing to optimize the development of stem cell-targeted cancer drugs. The alliance will seek to accelerate the development of Cellectis UCART123 in AML. Cellectis proprietary allogeneic CAR T-cell platform utilizes T-cells (immune cells) from healthy donors. The T-cells are engineered with a Chimeric Antigen Receptor (CAR), which enables them to detect specific proteins (antigens) expressed on malignant tumors. Large numbers of allogeneic CAR-modified T-cells are grown in the laboratory and then infused into a patient. The enhanced cells are designed to recognize and attack stem cells harboring the CD123 antigen, which is present on AML blast and stem cells. To enhance safety and minimize toxicity for patients, the company's gene-editing process features customized control properties that seek to prevent the T cells from inappropriately attacking healthy tissues.
Dr. Silvia C. Formenti Joins as Chair of the Newly Established Department of Radiation Oncology at Weill Cornell Medical College, Effective April 15
Mar 4 15
Dr. Silvia C. Formenti has been appointed chair of the newly established Department of Radiation Oncology at Weill Cornell Medical College, effective April 15. Dr. Formenti, currently the chair of radiation oncology at New York University Langone Medical Center, has also been named the associate director of radiation oncology at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College.
Weill Cornell Medical College Announces Change of Chairman, Effective Jan. 1, 2015
Dec 9 14
After 20 years of bold and visionary leadership that has transformed Weill Cornell Medical College into a global healthcare enterprise, Sanford I. Weill will retire as chair of the Weill Cornell Board of Overseers on Jan. 1, 2015. Jessica M. Bibliowicz, a successful entrepreneur in the financial services business for nearly three decades, who has served on the Board of Overseers for the past decade, will succeed Mr. Weill, the new chair emeritus. In collaboration with medical college leadership, Ms. Bibliowicz will help lead Weill Cornell as it continues to break new ground in New York and abroad by expanding its clinical enterprise and forging public-private partnerships that accelerate groundbreaking scientific discoveries for patients. Working closely with Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College, Ms. Bibliowicz will help guide its transformation of medical education and drive dialogue on innovative healthcare delivery models that optimize the value and quality of patient care. Currently, Ms. Bibliowicz is a senior advisor at Bridge Growth Partners and serves on the board of directors of Sotheby's; Realogy; and the Asia Pacific Fund. She is a board director/trustee of Prudential Insurance Funds and is also on the board of Jazz at Lincoln Center.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|